thalidomide has been researched along with Genetic Predisposition in 22 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide is commonly used in treatment of multiple myeloma (MM)." | 7.91 | Polymorphisms in the promotor region of the CRBN gene as a predictive factor for peripheral neuropathy in the course of thalidomide-based chemotherapy in multiple myeloma patients. ( Chocholska, S; Homa-Mlak, I; Hus, M; Jankowska-Łęcka, O; Mazurek, M; Małecka-Massalska, T; Mielnik, M; Mlak, R; Szczyrek, M; Szudy-Szczyrek, A, 2019) |
| "Thalidomide is widely used for several diseases; however, it causes malformations in embryos exposed during pregnancy." | 7.91 | The role of ESCO2, SALL4 and TBX5 genes in the susceptibility to thalidomide teratogenesis. ( Fraga, LR; Gomes, JDA; Kowalski, TW; Macedo, GS; Sanseverino, MTV; Schuler-Faccini, L; Vianna, FSL, 2019) |
| "The role of TNF-α promoter polymorphisms in the development of multiple myeloma (MM) were tested in 210 patients and 218 healthy individuals and their impact on the clinical outcome were evaluated in 98 patients treated with thalidomide and dexamethasone (Thal+Dex) regimen." | 7.76 | Role of the TNF-α promoter polymorphisms for development of multiple myeloma and clinical outcome in thalidomide plus dexamethasone. ( Chen, B; Du, J; Fu, W; Hou, J; Jiang, H; Yuan, Z; Zhang, C, 2010) |
| "We analyzed DNA from 1,495 patients with multiple myeloma." | 5.37 | Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. ( Child, JA; Corthals, SL; Davies, FE; Dickens, NJ; Durie, BG; Goldschmidt, H; Gregory, WM; Johnson, DC; Lokhorst, HM; Morgan, GJ; Ross, FM; Sonneveld, P; Van Ness, B; Walker, BA, 2011) |
| "Thalidomide is commonly used in treatment of multiple myeloma (MM)." | 3.91 | Polymorphisms in the promotor region of the CRBN gene as a predictive factor for peripheral neuropathy in the course of thalidomide-based chemotherapy in multiple myeloma patients. ( Chocholska, S; Homa-Mlak, I; Hus, M; Jankowska-Łęcka, O; Mazurek, M; Małecka-Massalska, T; Mielnik, M; Mlak, R; Szczyrek, M; Szudy-Szczyrek, A, 2019) |
| "Thalidomide is widely used for several diseases; however, it causes malformations in embryos exposed during pregnancy." | 3.91 | The role of ESCO2, SALL4 and TBX5 genes in the susceptibility to thalidomide teratogenesis. ( Fraga, LR; Gomes, JDA; Kowalski, TW; Macedo, GS; Sanseverino, MTV; Schuler-Faccini, L; Vianna, FSL, 2019) |
| " Established risk factors in IBD colitis inpatients with TE included: indwelling catheter (4/10), first-degree family member with TE (2/10), hereditary thrombophilia (3/10), smoking (1/10), oral contraceptive (1/5 females), and thalidomide (1/10)." | 3.79 | Risk factors, morbidity, and treatment of thrombosis in children and young adults with active inflammatory bowel disease. ( Atkinson, BJ; Bousvaros, A; Harney, KM; Levine, AE; Lightdale, JR; Trenor, CC; Verhave, M; Zitomersky, NL, 2013) |
| "The role of TNF-α promoter polymorphisms in the development of multiple myeloma (MM) were tested in 210 patients and 218 healthy individuals and their impact on the clinical outcome were evaluated in 98 patients treated with thalidomide and dexamethasone (Thal+Dex) regimen." | 3.76 | Role of the TNF-α promoter polymorphisms for development of multiple myeloma and clinical outcome in thalidomide plus dexamethasone. ( Chen, B; Du, J; Fu, W; Hou, J; Jiang, H; Yuan, Z; Zhang, C, 2010) |
| "The hypothesis that brain stem injury plays a role in the autism spectrum disorders was suggested by evidence that exposure to thalidomide during the earliest stages of brain development increases the risk of autism spectrum disorders." | 3.71 | Converging evidence for brain stem injury in autism. ( Rodier, PM, 2002) |
| "Although peripheral neuropathies in children are often of genetic origin, acquired causes should be carefully looked for and ruled out also in the pediatric age." | 2.58 | Peripheral neuropathy and gastroenterologic disorders: an overview on an underrecognized association. ( De' Angelis, GL; Di Mario, F; Fusco, C; Gaiani, F; Leandro, G; Pisani, F; Spagnoli, C, 2018) |
| "Multiple myeloma is characterised by clonal proliferation of malignant plasma cells, and mounting evidence indicates that the bone marrow microenvironment of tumour cells has a pivotal role in myeloma pathogenesis." | 2.45 | Multiple myeloma. ( Anderson, KC; Breitkreutz, I; Podar, K; Raab, MS; Richardson, PG, 2009) |
| "Crohn's disease is a chronic inflammatory disease, which may involve any part of the gastrointestinal tract, including the oral cavity." | 2.41 | [Oral aspects of Crohn's disease]. ( Brand, HS; Scheper, HJ, 2000) |
| "Thalidomide is a drug responsible to a spectrum of congenital anomalies known as Thalidomide Embryopathy (TE), which includes mainly limb and heart defects." | 1.72 | Genetic evaluation of HAND2 gene and its effects on thalidomide embryopathy. ( Bremm, JM; do Amaral Gomes, J; Fraga, LR; Kowalski, TW; Rengel, BD; Schüler-Faccini, L; Vianna, FSL, 2022) |
| "Thalidomide is a drug used worldwide for several indications, but the molecular mechanisms of its teratogenic property are not fully understood." | 1.48 | Genetic susceptibility to thalidomide embryopathy in humans: Study of candidate development genes. ( Fraga, LR; Gomes, JDA; Kowalski, TW; Sanseverino, MTV; Schuler-Faccini, L; Tovo-Rodrigues, L; Vianna, FSL, 2018) |
| "Lenalidomide has significant antimyeloma activity but it is associated with a significant risk of venous thromboembolism (VTE)." | 1.39 | Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens. ( Bagratuni, T; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Gavriatopoulou, M; Kanelias, N; Kastritis, E; Kostouros, E; Politou, M; Roussou, M; Terpos, E, 2013) |
| "We analyzed DNA from 1,495 patients with multiple myeloma." | 1.37 | Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. ( Child, JA; Corthals, SL; Davies, FE; Dickens, NJ; Durie, BG; Goldschmidt, H; Gregory, WM; Johnson, DC; Lokhorst, HM; Morgan, GJ; Ross, FM; Sonneveld, P; Van Ness, B; Walker, BA, 2011) |
| "The GENetic DEterminants of Restenosis (GENDER) project included 3104 patients who underwent a successful PCI." | 1.33 | Tumor necrosis factor-alpha plays an important role in restenosis development. ( 't Hart, LM; Agema, WR; Boesten, LS; de Maat, MP; de Vries, MR; de Winter, RJ; Doevendans, PA; Frants, RR; Havekes, LM; Jukema, JW; Monraats, PS; Pires, NM; Quax, PH; Schepers, A; Tio, RA; van der Laarse, A; van der Wall, EE; van Vlijmen, BJ; Waltenberger, J; Zwinderman, AH, 2005) |
| "Actinic prurigo is a specific familial photodermatosis of uncertain pathogenesis." | 1.31 | Effectors of inflammation in actinic prurigo. ( Arrese, JE; Cortés-Franco, R; Dominguez-Soto, L; Guevara, E; Hojyo-Tomoka, MT; Piérard, GE; Vega-Memije, E, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (31.82) | 29.6817 |
| 2010's | 12 (54.55) | 24.3611 |
| 2020's | 3 (13.64) | 2.80 |
| Authors | Studies |
|---|---|
| Rengel, BD | 1 |
| Kowalski, TW | 5 |
| Bremm, JM | 1 |
| do Amaral Gomes, J | 1 |
| Schüler-Faccini, L | 5 |
| Vianna, FSL | 4 |
| Fraga, LR | 5 |
| Gomes, JDA | 3 |
| Garcia, GBC | 1 |
| Paixao-Cortes, VR | 1 |
| Recamonde-Mendoza, M | 1 |
| Sanseverino, MTV | 3 |
| Genova, E | 1 |
| Cavion, F | 1 |
| Lucafò, M | 1 |
| Pelin, M | 1 |
| Lanzi, G | 1 |
| Masneri, S | 1 |
| Ferraro, RM | 1 |
| Fazzi, EM | 1 |
| Orcesi, S | 1 |
| Decorti, G | 1 |
| Tommasini, A | 1 |
| Giliani, S | 1 |
| Stocco, G | 1 |
| Tovo-Rodrigues, L | 2 |
| Spagnoli, C | 1 |
| Pisani, F | 1 |
| Di Mario, F | 1 |
| Leandro, G | 1 |
| Gaiani, F | 1 |
| De' Angelis, GL | 1 |
| Fusco, C | 1 |
| Mlak, R | 1 |
| Szudy-Szczyrek, A | 1 |
| Mazurek, M | 1 |
| Szczyrek, M | 1 |
| Homa-Mlak, I | 1 |
| Mielnik, M | 1 |
| Chocholska, S | 1 |
| Jankowska-Łęcka, O | 1 |
| Małecka-Massalska, T | 1 |
| Hus, M | 1 |
| Macedo, GS | 1 |
| Zitomersky, NL | 1 |
| Levine, AE | 1 |
| Atkinson, BJ | 1 |
| Harney, KM | 1 |
| Verhave, M | 1 |
| Bousvaros, A | 1 |
| Lightdale, JR | 1 |
| Trenor, CC | 1 |
| Bagratuni, T | 1 |
| Kastritis, E | 1 |
| Politou, M | 1 |
| Roussou, M | 1 |
| Kostouros, E | 1 |
| Gavriatopoulou, M | 1 |
| Eleutherakis-Papaiakovou, E | 1 |
| Kanelias, N | 1 |
| Terpos, E | 1 |
| Dimopoulos, MA | 1 |
| Sanseverino, MT | 1 |
| Hutz, MH | 1 |
| Vianna, FS | 1 |
| Han, M | 1 |
| Murugesan, A | 1 |
| Bahlis, NJ | 1 |
| Song, K | 1 |
| White, D | 1 |
| Chen, C | 1 |
| Seftel, MD | 1 |
| Howsen-Jan, K | 1 |
| Reece, D | 1 |
| Stewart, K | 1 |
| Xie, Y | 1 |
| Hay, AE | 1 |
| Shepherd, L | 1 |
| Djurfeldt, M | 1 |
| Zhu, L | 1 |
| Meyer, RM | 1 |
| Chen, BE | 1 |
| Reiman, T | 1 |
| Kasamatsu, T | 1 |
| Saitoh, T | 1 |
| Ino, R | 1 |
| Gotoh, N | 1 |
| Mitsui, T | 1 |
| Shimizu, H | 1 |
| Matsumoto, M | 1 |
| Sawamura, M | 1 |
| Yokohama, A | 1 |
| Handa, H | 1 |
| Tsukamoto, N | 1 |
| Murakami, H | 1 |
| Butrym, A | 1 |
| Łacina, P | 1 |
| Rybka, J | 1 |
| Chaszczewska-Markowska, M | 1 |
| Mazur, G | 1 |
| Bogunia-Kubik, K | 1 |
| Tewari, P | 1 |
| Kenny, E | 1 |
| Staines, A | 1 |
| Chanock, S | 1 |
| Browne, P | 1 |
| Lawler, M | 1 |
| Raab, MS | 1 |
| Podar, K | 1 |
| Breitkreutz, I | 1 |
| Richardson, PG | 1 |
| Anderson, KC | 1 |
| Du, J | 1 |
| Yuan, Z | 1 |
| Zhang, C | 1 |
| Fu, W | 1 |
| Jiang, H | 1 |
| Chen, B | 1 |
| Hou, J | 1 |
| Johnson, DC | 1 |
| Corthals, SL | 1 |
| Walker, BA | 1 |
| Ross, FM | 1 |
| Gregory, WM | 1 |
| Dickens, NJ | 1 |
| Lokhorst, HM | 1 |
| Goldschmidt, H | 1 |
| Davies, FE | 1 |
| Durie, BG | 1 |
| Van Ness, B | 1 |
| Child, JA | 1 |
| Sonneveld, P | 1 |
| Morgan, GJ | 1 |
| Rodier, PM | 1 |
| Monraats, PS | 1 |
| Pires, NM | 1 |
| Schepers, A | 1 |
| Agema, WR | 1 |
| Boesten, LS | 1 |
| de Vries, MR | 1 |
| Zwinderman, AH | 1 |
| de Maat, MP | 1 |
| Doevendans, PA | 1 |
| de Winter, RJ | 1 |
| Tio, RA | 1 |
| Waltenberger, J | 1 |
| 't Hart, LM | 1 |
| Frants, RR | 1 |
| Quax, PH | 1 |
| van Vlijmen, BJ | 1 |
| Havekes, LM | 1 |
| van der Laarse, A | 1 |
| van der Wall, EE | 1 |
| Jukema, JW | 1 |
| Arrese, JE | 1 |
| Dominguez-Soto, L | 1 |
| Hojyo-Tomoka, MT | 1 |
| Vega-Memije, E | 1 |
| Cortés-Franco, R | 1 |
| Guevara, E | 1 |
| Piérard, GE | 1 |
| Scheper, HJ | 1 |
| Brand, HS | 1 |
| Finnell, RH | 1 |
| Waes, JG | 1 |
| Eudy, JD | 1 |
| Rosenquist, TH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Trial of the Anti -PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) + Lenalidomide + Dexamethasone as Post Autologous Transplant Consolidation in Patients With High-risk Multiple Myeloma[NCT02906332] | Phase 2 | 12 participants (Actual) | Interventional | 2016-12-12 | Terminated (stopped due to FDA Hold Due to Updated Risks) | ||
| Multicenter, Interventional, Single-arm, Phase IV Study Evaluating Tolerability of Eribulin and Its Relationship With a Set of Polymorphisms in an Unselected Population of Female Patients With Metastatic Breast Cancer[NCT02864030] | Phase 4 | 200 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Assessed by the investigator per International Myeloma Working Group criteria(IMWG) uniform response criteria. Result reflects number of participants whose best overall response qualified as sCR, CR, or VGPR in 2 year follow up period. (NCT02906332)
Timeframe: Every 3 weeks (day 1 of every 21-day treatment cycle +/- 7 days) through 12 weeks.
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab + Lenalidomide | 11 |
Safety will be assessed by quantifying the toxicities and grades experienced by subjects who have received pembrolizumab (MK-3475), lenalidomide and dexamethasone, including serious adverse events (SAEs). Result reflects count of participants who experienced an SAE. (NCT02906332)
Timeframe: Up to 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab + Lenalidomide | 1 |
Assessed at 12 months; Subjects without documented PD or death will be censored at the last disease assessment date. Those who died without documented PD will be censored at the time of death. Result reflects count of participants who had progressed at 12 months. (NCT02906332)
Timeframe: Time from Day 0 (transplant) and date of enrollment to study completion (through 12 weeks) by investigator assessment.
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab + Lenalidomide | 10 |
PFS will be assessed from the date of ASCT, with day 0 defined as date of stem cell infusion (if tandem transplant the 2nd of 2 transplants will be used) until the date of progression, defined as the date at which the patient starts the next line of therapy or the date of death. (NCT02906332)
Timeframe: Up to 3 years
| Intervention | months (Median) |
|---|---|
| Pembrolizumab + Lenalidomide | 27.6 |
4 reviews available for thalidomide and Genetic Predisposition
| Article | Year |
|---|---|
Peripheral neuropathy and gastroenterologic disorders: an overview on an underrecognized association.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Campylobacter Infections; Celiac Disease; Child; Comor | 2018 |
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therap | 2009 |
[Oral aspects of Crohn's disease].
Topics: Crohn Disease; Dental Caries; Genetic Predisposition to Disease; Humans; Immunosuppressive Agents; O | 2000 |
Molecular basis of environmentally induced birth defects.
Topics: Abnormalities, Drug-Induced; Animals; Embryonic and Fetal Development; Female; Gene Expression Regul | 2002 |
18 other studies available for thalidomide and Genetic Predisposition
| Article | Year |
|---|---|
Genetic evaluation of HAND2 gene and its effects on thalidomide embryopathy.
Topics: Abnormalities, Multiple; Basic Helix-Loop-Helix Transcription Factors; Female; Fetal Diseases; Genet | 2022 |
CRL4-Cereblon complex in Thalidomide Embryopathy: a translational investigation.
Topics: Adaptor Proteins, Signal Transducing; Adolescent; Adult; Child; Embryo, Mammalian; Embryonic Develop | 2020 |
Biomarkers and Precision Therapy for Primary Immunodeficiencies: An In Vitro Study Based on Induced Pluripotent Stem Cells From Patients.
Topics: Ataxia Telangiectasia; Autoimmune Diseases of the Nervous System; Biomarkers; Cell Line; Cell Prolif | 2020 |
Genetic susceptibility to thalidomide embryopathy in humans: Study of candidate development genes.
Topics: Abnormalities, Drug-Induced; Female; Genetic Predisposition to Disease; Genotype; Humans; Infant, Ne | 2018 |
Polymorphisms in the promotor region of the CRBN gene as a predictive factor for peripheral neuropathy in the course of thalidomide-based chemotherapy in multiple myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Female; Genetic Predisposition to Disease; Humans; Immunosuppressive | 2019 |
The role of ESCO2, SALL4 and TBX5 genes in the susceptibility to thalidomide teratogenesis.
Topics: Abnormalities, Multiple; Acetyltransferases; Brazil; Cell Line; Chromosomal Proteins, Non-Histone; C | 2019 |
Risk factors, morbidity, and treatment of thrombosis in children and young adults with active inflammatory bowel disease.
Topics: Adolescent; Adult; Antibodies, Anticardiolipin; Anticoagulants; Catheterization; Catheters, Indwelli | 2013 |
Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens.
Topics: Acenocoumarol; Age Factors; Antineoplastic Agents; Aspirin; Female; Genetic Predisposition to Diseas | 2013 |
New Findings in eNOS gene and Thalidomide Embryopathy Suggest pre-transcriptional effect variants as susceptibility factors.
Topics: Adolescent; Adult; Brazil; Child; Female; Fetal Diseases; Gene Frequency; Genetic Predisposition to | 2016 |
A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Canada; Genetic Predisposition to Disease; Hematopoi | 2016 |
Polymorphism of IL-10 receptor β affects the prognosis of multiple myeloma patients treated with thalidomide and/or bortezomib.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; | 2017 |
Cereblon and IRF4 Variants Affect Risk and Response to Treatment in Multiple Myeloma.
Topics: Adaptor Proteins, Signal Transducing; Alleles; Antineoplastic Combined Chemotherapy Protocols; B-Lym | 2016 |
Genetic variants in XRRC5 may predict development of venous thrombotic events in myeloma patients on thalidomide.
Topics: Angiogenesis Inhibitors; Case-Control Studies; DNA Helicases; Genetic Predisposition to Disease; Hum | 2009 |
Role of the TNF-α promoter polymorphisms for development of multiple myeloma and clinical outcome in thalidomide plus dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies | 2010 |
Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Female; Gene | 2011 |
Converging evidence for brain stem injury in autism.
Topics: Autistic Disorder; Brain Stem; Child; Genetic Predisposition to Disease; Homeodomain Proteins; Human | 2002 |
Tumor necrosis factor-alpha plays an important role in restenosis development.
Topics: Aged; Alleles; Angina Pectoris; Angiography; Angioplasty, Balloon, Coronary; Animals; Constriction, | 2005 |
Effectors of inflammation in actinic prurigo.
Topics: Adolescent; Adult; Child; Female; Genetic Predisposition to Disease; Humans; Immunohistochemistry; I | 2001 |